More on DVAX

- Summary
- Chart
- Profile
- Historical


- Earnings (-106.7% Growth)
- Ratings (10.0 Score)
- Holders
- FDA Archive


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (2/27/24)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

DVAX Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 23.02M
Marketable securities
Accounts receivable
Prepaid expenses and other current assets 5.67M
Total current assets 117.51M
Property and equipment, net 18.74M
Goodwill 2.1M
Other intangible assets, net
Restricted cash 615K
Other assets 330K
Total assets 139.3M
Current liabilities:
Accounts payable 3.8M
Accrued liabilities 21.99M
Deferred revenues 0
Total current liabilities 30.49M
Deferred revenues, noncurrent
Long-term note payable to Symphony Dynamo Holdings LLC
Long-term contingent liability to Symphony Dynamo Holdings LLC
Other long-term accrued liabilities 541K
Commitments and contingencies (Note 6) 0
Stockholders' equity:
Preferred stock: $0.001 par value; 5,000 shares authorized and no shares issued and outstanding at June 30, 2011 and December 31, 2010 0
Common stock: $0.001 par value; 250,000 and 150,000 shares authorized at June 30, 2011 and December 31, 2010, respectively; 123,418 and 115,611 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 39K
Additional paid-in capital
Accumulated other comprehensive loss:
Unrealized gain (loss) on marketable securities available-for-sale
Cumulative translation adjustment
Total accumulated other comprehensive loss -2.41M
Accumulated deficit -790.43M
Total stockholders' equity 108.27M
Total liabilities and stockholders' equity 139.3M